Drug intelligence / Profile preview

cyclo(prolylglycyl)

Development stage
Phase 3
Lead developer
Biomed Industries
Modality
Small Molecules
Administration
Oral
01

Overview

Cyclo(prolylglycyl), also known as Traneurocin and by the code name NA-831, is a small molecule cyclic dipeptide belonging to the class of diketopiperazines. It is an endogenous neuroactive peptide found in human plasma and cerebrospinal fluid. Cyclo(prolylglycyl) acts as a modulator of AMPA receptors and has been shown to exert neuroprotective effects that are dependent on both AMPA receptor and TrkB receptor activation. It increases brain-derived neurotrophic factor (BDNF) in cell culture studies. The compound is under investigation for several neurological conditions including Alzheimer's disease, fragile X syndrome, Rett syndrome, major depressive disorder (MDD), and COVID-19-induced neuropathy. Its mechanism involves modulation of synaptic plasticity pathways relevant to cognition and neuroprotection[1][2][7].

Brand names
Traneurocin
Other names
cyclo(pro-gly)cyclo(pro-O-gly)(S)-Hexahydropyrrolo(1,2-a)pyrazine-1,4-dione-4-17Ocyclic glycine-prolinecGPcycloprolylglycine
02

Targets

AMPAR (AMPA receptor)NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on cyclo(prolylglycyl).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclo(prolylglycyl).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call